ArticleArchives of medical science : AMS2025
Early and simple laboratory markers of poor outcome in children with inflammatory bowel disease.
Article in Archives of medical science : AMS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Personalized medicine in inflammatory bowel disease (IBD) aims to achieve maximum effectiveness through rapid induction and maintenance of remission. To achieve this goal, reliable predictors of disease course are needed. The aim of this study was to identify early markers of IBD's poor course understood as the need for anti-tumor necrosis factor (anti-TNF-α) treatment. Material and methods: We analyzed the clinical, laboratory, radiological, and endoscopic data of children with IBD. These parameters were assessed at the time of diagnosis (T0) and 8-12 weeks (T1) after the start of induction therapy. The results of patients who did not require anti-TNF-α treatment were compared to children who needed such treatment during the 2-year observation time. Results: 58.14% of patients with Crohn's disease (CD) and 31.71% of patients with ulcerative colitis (UC) required biological therapy. Patients with CD and UC receiving biological therapy, compared with those without, differed in selected clinical and laboratory parameters both at T0 and T1. In multivariate analysis, the risk of anti-TNF-α therapy in patients with CD was associated with the lack of normalization of mean corpuscular volume (MCV) and Pediatric Crohn's Disease Activity Index (PCDAI). In patients with UC, higher albumin levels reduced this risk. Conclusions: In children with IBD, disease activity and concentrations of selected biochemical parameters assessed within 3 months after diagnosis may be helpful in predicting a poor outcome of CD and UC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.